I think the stock can go to $10 in short order. Many tailwinds for 2015 and its a very cheap stock especially as estimates will keep getting adjusted higher. Shorts will try to push it down but it probably won't work this time because the numbers are going against them.
37% increase in shipments despite the outage, big bottom line beat. 23% short interest you are going to be tripping over yourselves trying to cover as the analysts raise price targets and estimates for 2015
Sentiment: Strong Buy
Agree. Pretty much all of my watch list of 50 or so small biotech stocks were down big today with IBB off nearly 3%. Usually that means the small caps will be down double plus we may be getting a bunch of tax loss selling before people pack it in for holiday vacations. I was hoping this was over for ATHX though considering how weak it has been.
While I would be a lot more confident seeing management stepping up to buy large blocks of stock now, I do acknowledge that the CEO and the rest of the management already have a lot of stock. The cash component of CEO Gil's compensation is more in line with the norms if you don't consider the shares and options he was granted. I am OK with the latter because he only makes money if stroke goes well and all shareholders make money and to date has only sold for tax vesting purposes.
According to the 10K, the CEO made $569K in total cash comp in 2013, $537K in 2012 and $444K in 2011. He owns 917K shares according to the latest filings (and also options) so his real wealth will be made if he can deliver on stroke or other indications.
My discussion with the company about the expansion of the end points was positive. My view is that even mixed results could be enough for Japan approval so why not give themselves the best odds possible.
Yes the science and the credentials of mgmt have been part of the reason I have stubbornly held on but the last few months have been brutal with so little info from the management. It's my biggest dollar and percentage loss ever in 25+ years of investing. What I really don't get are the shorts. Even if the odds are slim you can't be short a name that will go to double digits with even a small amount of efficacy on stroke. To me the only debate at this level is whether to be long or be out all together.
That is fair. Look I am not trying to bash and your posts have provided a huge amount of great information over time. I don't post much because what is the point really??? If the facts change ie japan partnership or a few smart institutions start adding I will reevaluate. I have been looking for any reason to stay because like you I recognize that a positive outcome on stroke is a life changing amount of money.
I strongly disagree about the hedge funds being unsophisticated. I have two friends that work as analysts in hedge fund health care pods and they have scored big on a few of the small cap bios this year. Even those small positions represented 100+ hours of mgmt calls, discussions with industry expert networks, etc . The institutional ownership has been reduced substantially since UC to a mid teens percentage. Is it possible that everyone has missed this? I suppose there is a very small probability. As to sentiment it is not like I am the weak hand and bailed as soon as UC flopped. I have anguished over this stock for hundreds of hours this year reading every message board post, listening to every presentation, reading every scientific article but at this point being objective there is no conspiracy to keep this down etc.
The fact that ATHX has stayed this low since the UC failure for more than a few weeks tells me the odds of failure on stroke are probably 99%. Do you honestly think that hedge funds wouldn't be ALL OVER this name with such enormous upside if phase 2 goes well? If this even had 20% odds you would see tons of hedge funds willing to hold small $1-2m lotto ticket positions. If you have a $200m book and make this a 1% position it won't hurt you if it's a zero but can make your year if the data is good. The funds have teams of analysts and enormous resources to consult with medical experts and many of the healthcare sector portfolio managers have medical backgrounds and PhDs themselves. There has been ample time to DD this company since UC failed and almost all the institutions have sold. Furthermore, the CEO and CFO have not bought a single share in recent months. I mean come on what does that tell you. It is impossible that they have been restricted or prevented from buying shares this entire time. I have been long for over a year and now down a ton and will be taking the write off before year end unless by some miracle there is actual good news.
Regardless of which way this breaks the company should investigate the stock action in the past several days including the recent bear raid. Let short sellers explain their plunging activities to FINRA because this kind of BULLSH** costs really hurts individual investors. GLTA
Ask yourself why Dodd, who sold a company for $1.5B previously, would bother with AEZS if he didn't see major potential? It's not like he needs the money at this point...He seems to know the ropes with the FDA quite well and has prepared for a major rollout in January if approved. In the Q2 call he said the 50 reps will get in front of 100% of the targeted endocrinologists twice within the first 6 months. Mind you this is to replace the insulin tolerance test which they don't like to begin with. You harp on the potential dilution to fund a roll-out but upon approval I think this is about as low risk of a roll-out as we get in small biotech.
Sentiment: Strong Buy
Yes I saw that CRR plunged in the past 2 months after they lost a major customer and lowered their sales outlook. I have also seen two consultant market outlook reports published this month on frac proppant that estimate both sand and ceramics will grow 9-11% annually 2014-2018 (varies a bit by report). With sand the barriers to entry seem lower than ceramics.
Doing some initial research on the space and hoping that someone with an oil services background can answer what the applications for ceramic are vs. sand and the cost/benefits of each at $80 oil. It seems that ceramic is preferred for deeper wells where crushing is a factor. What percentage of wells fall in this category?
As a shareholder here for over a year I have several serious issues with the CEO. First, he clearly pumped the stock heavily in late 2013-early 2014 and made misleading statements before bagging holders with a big raise at $4.10. Then after the UC failure he completely blew off the outcome and tried to spin it as completely irrelevant to stroke. Second, he has wasted a lot of time running back and forth to Japan for something that is not even proven to work yet and ramping the manufacturing. Third, the CEO and a few other key people are making a GROSS amount of compensation given the current market cap and the lack of any tangible positive results. Finally, the CEO has repeatedly stated how undervalued the stock is yet has not bought a single share in recent months.
People are selling because Gil now has zero credibility and this stock has been relegated to a pump and dump.
The bottom line is the stock has not acted well for months now and it was easy to overrule my normal loss discipline when I saw major bulls cheerleading and adding all the way down.
It is obvious whoever emerges as the winners in mobile payments will be great investments but this is a major fundamental blow that even the most die-hard bull has to honestly acknowledge.
There's blood all right. It's my portfolio bleeding to death today with this junk. -2% hit to my portfolio on a spec name. I forced myself to liquidate.
In retrospect there were many signs this was in big trouble but hindsight is just that....Huge pop on IBM and immediately sold off, no Apple announcement and slid further, very little communication from Monitise to its shareholders while the stock was falling off a cliff and being attacked by shorts. I also learned a painful lesson about putting too much weight on big names like Cooperman/Kass. Without their involvement I would not have invested and certainly it would have been a 2-3% position tops (it was a 7% position unfortunately).
Anyway, good luck to everyone here but when major negative news like this hits I have to admit that I am wrong and cut my losses. IBM may very well seize this opportunity but hoping for a takeout is not an investment strategy for me.
Nice job. You completely botched the second indication presentation and now you are stuffing us with another round of dilution at the 52 week low on the stock. I am selling my entire position tomorrow. Lesson learned do not invest in sh** management.
Already have a big position in this so not adding when the stock is getting smashed and we don't know why. Bear raid or not, someone definitely knows something IMO. I am holding because I firmly believe MONI is right in the middle of a huge wave in payments and will somehow capitalize but I hate being on the other side of hedge funds shorting the stock.
Something is definitely wrong. MONI is down 5% in London now. Maybe we are looking at more bad news on the guidance? This is beyond no Apple news.